Morphine Extended-Release Capsules and Nifediac CC
Determining the interaction of Morphine Extended-Release Capsules and Nifediac CC and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:NIFEdipine and morphine may have additive effects in lowering your blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. These side effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.
MANAGEMENT: Caution is advised during coadministration of these agents. Close monitoring for development of hypotension is recommended. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.
- Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139
- Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6
- Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1
- Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40
- Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75
- Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595
Generic Name: morphine
Brand name: Arymo ER, Kadian, MorphaBond ER, MS Contin, Avinza, Duramorph PF, Infumorph, Mitigo, RMS, Roxanol
Synonyms: Morphine, Morphine (Systemic)
Generic Name: nifedipine
Brand name: Adalat CC, Afeditab CR, Nifediac CC, Nifedical XL, Procardia, Procardia XL, Adalat
Synonyms: Nifediac CC (Oral)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Morphine Extended-Release Capsules-Nifedical XL
- Morphine Extended-Release Capsules-Nifedipine
- Morphine Extended-Release Capsules-Nifedipine Capsules
- Morphine Extended-Release Capsules-Nifedipine Extended-Release Tablets
- Morphine Extended-Release Capsules-Niferex
- Morphine Extended-Release Capsules-Niferex Elixir
- Nifediac CC-Morphine Immediate-Release Tablets and Capsules
- Nifediac CC-Morphine injection
- Nifediac CC-Morphine Injection PF
- Nifediac CC-Morphine Long-Acting Tablets
- Nifediac CC-Morphine Oral Concentrate (20 mg/mL)
- Nifediac CC-Morphine Oral Solution